Published in AIDS Weekly, May 23rd, 2005
The consolidated net loss was $3.6 million, or $0.14 per share, as compared to a net loss of $2.9 million, or $0.12 per share, in the same period of 2004. At March 31, 2005, the company had cash, cash equivalents, investments and interest receivable of $30.0 million.
Revenues for the first quarter of 2005 were $256,000 as compared to first quarter 2004 revenues of $811,000. First quarter 2005 revenues were from Sangamo's enabling technology research agreements, federal government research grants and human therapeutics collaborations. Revenues in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.